Changes in extracellular water and left ventricular mass in peritoneal dialysis patients
- PMID: 33789386
- PMCID: PMC8041629
- DOI: 10.23876/j.krcp.20.153
Changes in extracellular water and left ventricular mass in peritoneal dialysis patients
Abstract
Background: Increasing number of peritoneal dialysis (PD) patients are reported to have increased left ventricular hypertrophy (LVH), a major risk factor for cardiovascular mortality. We wished to determine which factors were most associated with changes in left ventricular mass index (LVMI).
Methods: We reviewed patient and treatment factors in prevalent PD patients with repeat echocardiograms 18 to 24 months apart, with corresponding bioimpedance measurements of extracellular water (ECW) and serum N-terminal pro-brain natriuretic peptide (NT-proBNP).
Results: We studied 60 patients (34 males, 35 with diabetes) who were treated with PD for a median of 14 months (2.5-26.3 months). All but one had LVH; on repeat echocardiography, there was no overall change in LVMI (106 [84-127] g/m2 vs. 108 [91-122] g/m2) despite a loss of residual renal function. Left ventricular mass increased in 34 (56.7%), and the percent change in LVMI was associated with percent change in NT-proBNP (r = 0.51, p = 0.017) and ECW/height (r = 0.32, p = 0.029), but not with ECW/total body water or changes in systolic or mean arterial pressure, urine output, 24-hour PD ultrafiltration, or net sodium balance. Only ECW/height remained independently associated with the percent change in LVMI in a multivariable model (odds ratio, 1.25; 95% confidence interval, 1.08-1.36; p = 0.007).
Conclusion: In this observational longitudinal report, a reduction in ECW/height was associated with regression of LVMI, whereas an increased ECW/height was associated with increased LVMI. As there was no corresponding association with systolic or mean arterial pressure, then volume expansion would appear to be a more significant factor in determining LVH than blood pressure.
Keywords: Hypertension; Hypertrophy; Peritoneal dialysis; Pro-brain natriuretic peptide (1-76); Water.
Conflict of interest statement
All authors have no conflicts of interest to declare.
Figures
References
-
- Banshodani M, Kawanishi H, Moriishi M, Shintaku S, Tsuchiya S. Association between dialysis modality and cardiovascular diseases: a comparison between peritoneal dialysis and hemodialysis. Blood Purif. 2020;49:302–309. - PubMed
-
- Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186–192. - PubMed
-
- Hüting J, Alpert MA. Progression of left ventricular hypertrophy in end-stage renal disease treated by continuous ambulatory peritoneal dialysis depends on hypertension and hypercirculation. Clin Cardiol. 1992;15:190–196. - PubMed
-
- Wang AY, Wang M, Woo J, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol. 2004;15:2186–2194. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials